# Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease

> **NCT00886951** · PHASE1 · TERMINATED · sponsor: **Institute for Neurodegenerative Disorders** · enrollment: 2 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** I123MNI388/I123MNI390

## Key facts

- **NCT ID:** NCT00886951
- **Lead sponsor:** Institute for Neurodegenerative Disorders
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** There seemed to be no uptake of the ligand in the areas of the brain expected for subjects with amyloid.
- **Last updated:** 2019-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00886951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00886951, "Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00886951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*